Immunome, Inc. $IMNM Shares Sold by Granahan Investment Management LLC

Granahan Investment Management LLC trimmed its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 29.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 307,021 shares of the company’s stock after selling 128,102 shares during the period. Granahan Investment Management LLC’s holdings in Immunome were worth $6,715,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. KBC Group NV bought a new stake in shares of Immunome during the 1st quarter valued at about $60,000. Strs Ohio acquired a new stake in Immunome during the fourth quarter worth about $64,000. Assetmark Inc. lifted its holdings in Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after acquiring an additional 1,442 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in Immunome in the fourth quarter worth about $121,000. Finally, BNP Paribas Financial Markets boosted its stake in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares during the period. 44.58% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Immunome

In other news, insider Kinney Horn sold 1,092 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $25.00, for a total value of $27,300.00. Following the transaction, the insider directly owned 1,092 shares of the company’s stock, valued at approximately $27,300. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $19.85, for a total value of $1,091,750.00. Following the sale, the insider owned 15,805 shares of the company’s stock, valued at approximately $313,729.25. This represents a 77.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 472,142 shares of company stock worth $10,262,648 over the last 90 days. 7.21% of the stock is currently owned by insiders.

Immunome Stock Performance

IMNM stock opened at $22.21 on Friday. The firm has a 50 day simple moving average of $21.02 and a 200 day simple moving average of $21.94. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $27.65. The stock has a market cap of $2.52 billion, a P/E ratio of -9.33 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. Sell-side analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on IMNM shares. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Citigroup restated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Leerink Partners cut their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Immunome in a research note on Tuesday. Finally, Barclays began coverage on Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.